Pipeline / Cell Therapy
RDC2
RCD2 is Celogos' and HRA Pharma's development candidate for treating anal incontinence. There are currently no satisfactory treatments available for this seriously debilitating condition, which affects around 1 in 25 people.
We are in the process of obtaining regulatory approval and expect to start clinical trials in early 2008.